When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies

• Published in: Therapeutic advances in neurological disorders Vol. 11; p. 1756285617749134
• Main Authors: Mantegazza, Renato, Antozzi, Carlo
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01.01.2018; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Monoclonal antibodies; Myasthenia gravis; Pathophysiology; Review; myasthenia gravis; treatment refractory; treatment intolerant; muscle-specific tyrosine kinase antibodies; acetylcholine receptor antibodies; monoclonal antibodies
• DOI: 10.1177/1756285617749134
• ISSN: 1756-2864; 1756-2856

The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half century, including substantial reductions in mortality and morbidity. However, approximately 10% of patients fails to respond adequately to current therapies and are considered treatment refractory, or treatment intolerant, and up to 80% have disease that fails to achieve complete stable remission. Although patients with autoantibodies to muscle-specific tyrosine kinase (anti-MuSK positive) are more likely to become treatment refractory than those with autoantibodies to the acetylcholine receptor (anti-AChR positive), each of these serotypes is substantially represented in the refractory MG population. Other risk factors for becoming treatment refractory include history of thymoma or thymectomy and female sex. A modified treatment algorithm for MG is proposed: patients who have disease that fails to respond to the stepwise approach to therapy, are treatment intolerant, or who require chronic rescue measures despite ongoing therapy, should be considered treatment refractory and emerging therapies should be considered. Three emerging monoclonal antibody-based therapies are discussed: the anti-B-cell agent rituximab; the terminal complement activation inhibitor eculizumab; and belimumab, which targets B-cell activating factor. Increased understanding of molecular pathophysiology and accurate antibody subtyping in MG should lead to the use of new therapeutic agents and successful management of treatment-refractory patients.